Mukuda Kengo, Inoue Ryo, Takata Miyako, Takazawa Kenji, Noma Hisashi, Morishima So, Oda Machi, Ma'arif Athok Shofiudin, Endo Yusuke, Sunada Hiroshi, Doi Ayumu, Matsuda Risa, Nishikawa Yukari, Okada Kensaku, Kitaura Tsuyoshi, Nakamoto Masaki, Yamasaki Akira, Chikumi Hiroki
Division of Infectious Diseases, Faculty of Medicine, Tottori University, Nishi-cho 86, Yonago, Tottori, 683-8503, Japan.
Laboratory of Animal Science, Department of Applied Biological Sciences, Faculty of Agriculture, Setsunan University, 45-1 Nagaotogecho, Hirakata, Osaka, 573-0101, Japan.
J Infect Chemother. 2025 Jan;31(1):102483. doi: 10.1016/j.jiac.2024.07.023. Epub 2024 Jul 30.
Antimicrobial treatment disrupts human microbiota. The effects of lascufloxacin (LSFX), a new fluoroquinolone, on human microbiota remains unknown. Therefore, in this study, we aimed to evaluate the effects of LSFX administration on the gut and salivary microbiota of healthy participants and those with pneumonia.
LSFX (75 mg, once a day, orally) was administered to healthy adults (healthy group) and adult patients with pneumonia (pneumonia group), and fecal and saliva samples were collected at five time points (Days 0, 3, 7, 14, and 28). Using the collected samples, α- and β-diversity indices, as well as bacterial composition of the gut microbiota and salivary microbiota were analyzed using next-generation sequencing.
In the healthy group, α-diversity indices of the gut and salivary microbiota were reduced and the lowest values on Day 3. For the gut microbiota, the Chao1 index (richness) recovered on Day 28, whereas the Shannon index (evenness) did not. In the salivary microbiota, the Chao1 and Shannon indices did not recover within the 28 day period. The β-diversity indices changed after LSFX administration and subsequently recovered on Day 28. After LSFX administration, the abundance of the Lachnospiraceae family decreased in the gut microbiota, and the abundance of Granulicatella, Streptococcus, Prevotella, Absconditabacteriales(SR1), and Saccharimonadales decreased in the salivary microbiota. In the pneumonia group, the α-diversity indices were lowest on Day 14 after LSFX administration.
We elucidated that LSFX administration differentially affected the gut and salivary microbiota; however, the richness and beta diversity recovered within 28 days.
抗菌治疗会破坏人类微生物群。新型氟喹诺酮类药物拉斯库氟沙星（LSFX）对人类微生物群的影响尚不清楚。因此，在本研究中，我们旨在评估服用LSFX对健康参与者和肺炎患者肠道及唾液微生物群的影响。
对健康成年人（健康组）和成年肺炎患者（肺炎组）口服LSFX（75毫克，每日一次），并在五个时间点（第0、3、7、14和28天）采集粪便和唾液样本。使用收集的样本，通过下一代测序分析肠道微生物群和唾液微生物群的α和β多样性指数以及细菌组成。
在健康组中，肠道和唾液微生物群的α多样性指数降低，在第3天达到最低值。对于肠道微生物群，Chao1指数（丰富度）在第28天恢复，而香农指数（均匀度）未恢复。在唾液微生物群中，Chao1和香农指数在28天内未恢复。服用LSFX后β多样性指数发生变化，随后在第28天恢复。服用LSFX后，肠道微生物群中毛螺菌科的丰度降低，唾液微生物群中 Granulicatella、链球菌属、普雷沃菌属、Absconditabacteriales（SR1）和糖单胞菌目的丰度降低。在肺炎组中，服用LSFX后第14天α多样性指数最低。
我们阐明了服用LSFX对肠道和唾液微生物群有不同影响；然而，丰富度和β多样性在28天内恢复。
